The DOI matches its Crossref record.
Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.
Abstract
A mouse/human chimeric antibody (ch14.18) was developed that reacts with the disialoganglioside GD2 on the surface of tumor cells of neuroectodermal origin. ch14.18 has the constant regions of a human IgG1 antibody and was expressed in a murine hybridoma. This antibody was produced in tissue culture at concentrations up to 180 mg/liter of spent culture fluid. ch14.18 was characterized and compared to 14.G2a, a murine mAb against GD2 of IgG2a isotype derived from the same parental hybridoma as ch14.18. Scatchard plot analysis of data from saturation binding studies on M21 melanoma cells showed identical binding for ch14.18 and 14.G2a. Indirect immunofluorescence revealed the same staining pattern for ch14.18 and 14.G2a on different melanoma cell lines. Both antibodies were equally capable of targeting M21 xenografts in athymic nude mice. ch14.18- and 14.G2a-activated human C-mediated cytolysis of melanoma cell; however, ch14.18-mediated antibody-dependent cytotoxicity of human effector cells against melanoma cells 50- to 100-fold more efficiently than 14.G2a.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Self-citationArmitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
Maloney, D., Liles, T., Czerwinski, D., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994) · Blood · doi:10.1182/blood.v84.8.2457.2457 · Cited by 762
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Berinstein, N. L., Grillo-López, A. J., White, C. A., Bence-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P., & Shen, D. (1998) · Annals of Oncology · doi:10.1023/a:1008416911099 · Cited by 526
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
Smith, B. A. H., & Bertozzi, C. R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00093-1 · Cited by 500
Ladenstein, R., Pötschger, U., Valteau-Couanet, D., Luksch, R., Castel, V., Yaniv, I., Laureys, G., Brock, P., Michon, J. M., Owens, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30578-3 · Cited by 418
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis.
Mueller, B. M., Reisfeld, R. A., Edgington, T. S., & Ruf, W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.11832 · Cited by 356
Self-citationDisialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
Nazha, B., Inal, C., & Owonikoko, T. K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01000 · Cited by 324
Erbacher, P., Bettinger, T., Belguise-Valladier, P., Zou, S., Coll, J.-L., Behr, J.-P., & Remy, J.-S. (1999) · The Journal of Gene Medicine · doi:10.1002/(sici)1521-2254(199905/06)1:3<210::aid-jgm30>3.0.co;2-u · Cited by 295
Yu, A. L., Uttenreuther-Fischer, M. M., Huang, C. S., Tsui, C. C., Gillies, S. D., Reisfeld, R. A., & Kung, F. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2169 · Cited by 250
Self-citationLow-density-lipoprotein-receptor-related protein (LRP) interacts with a GTP-binding protein
GORETZKI, L., & MUELLER, B. M. (1998) · Biochemical Journal · doi:10.1042/bj3360381 · Cited by 74
Self-citationTwo new trifunctional antibodies for the therapy of human malignant melanoma
Ruf, P., Jäger, M., Ellwart, J., Wosch, S., Kusterer, E., & Lindhofer, H. (2004) · International Journal of Cancer · doi:10.1002/ijc.11630 · Cited by 52
Immunotherapies for pediatric cancer: current landscape and future perspectives
Hutzen, B., Paudel, S. N., Naeimi Kararoudi, M., Cassady, K. A., Lee, D. A., & Cripe, T. P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09819-z · Cited by 44
Metadata
- Authors
- Mueller, B. M., Romerdahl, C. A., Gillies, S. D., & Reisfeld, R. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1990-02
- Volume
- 144
- Issue
- 4
- Pages
- 1382-1386
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1539497703
- Cited by
- 186
- References
- 0
- FWCI
- 13.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.